NEJM: Daremu monoantigen or is expected to treat a variety of autoimmune diseases such as systemic lupus erythematosus.

6, 2020 // -- In a recent study published in the international journal New England Journal of Medicine, scientists from the Charlett Medical University in Berlin and other institutions successfully treated two patients with the autoimmune disease systemic lupus erythematosus using one Targeting daratumumab, a monoclonal antibody that targets action plasma cells, the researchers were able to regulate abnormal immune memory processes in the patient's body, a treatment that induces a persistent clinical response while reducing the patient's systemic inflammatory performance.
Photo Source: Alexander/Charit?body's immune memory promotes the immune system's rapid and effective response to previously encountered pathogens, which are mediated by antibodies produced by memory T lymphocytes and plasma cells, which are located in special habitats in the bone marrow and can produce large numbers of antibodies for decades or even lifetimes to come.
In autoimmune diseases, the immune system considers certain parts of the body to be foreign and dangerous, and with the help of the body's immune memory, the immune system uses its own antibodies to produce an immune response, while systemic lupus erythematosus (SLE) is a typical autoimmune disease in which the antibodies produced by the patient's body resist the components of the autocytocyte nucleus.
This autoimmune response is often associated with inflammation that affects the body's skin, joints, or internal system (kidney, heart, or central nervous system), and traditionally patients rely on long-term inhibition of their body's immune response, but so far this therapy has not been used in mature memory plasma cells.
the study, researchers studied for the first time two lupus patients who did not respond to conventional therapies and analyzed the effectiveness and tolerance of plasma cell-specific therapies in treating both patients.
in a certain percentage of patients, currently available therapies do not seem to be effective in controlling the disease, so researchers urgently need to develop new targeted treatments. In the
article, the researchers focused on an anti-CD38 monoclonal antibody called Daremu monoantigen, which has been successfully used for many years to treat plasma cell cancer patients, and analyzed the key role of plasma cells in the development of autoimmune diseases, CD38 cell surface protein is considered a classic plasma cell Markers, however, have shown that in lupus patients, high levels of markers can often be detected in other active immune cells such as memory T lymphocytes and in blood and urine, which may be the ideal target for the development of new therapies, which may effectively eliminate pathologically altered immune cells.
The new treatment was given to two patients with life-threatening lupus whose symptoms included heart and kidney-induced inflammation and antibody-induced anaemia in the body, patients taking daremu monotherapy weekly, and their symptoms of the disease improved significantly after four weeks, while maintaining their levels of autoantibodies in the body's serum for several months, including After studying a variety of advanced technologies, including single-cell sequencing, the researchers confirmed that daremu monoantigen may have a positive effect on active T lymphocytes, which are thought to play a key role in the development of the disease, and that no associated side effects have been recorded in the two patients, although test results show a decrease in levels of protective antibodies in the body's blood, but this does not appear to be related to increased susceptivity to infection.
Finally, researcher Dr. Leonard Ostendorf noted that the results we observed in the treatment of SLE patients may shift to the treatment of autoimmune diseases in which other autoantibodies play a key role, and that further research will be needed to test the safety and effectiveness of Duremu monoantigen in the treatment of larger lupus patients, with late researchers planning to open a larger clinical study.
original source: Leonard Ostendorf, M.D., Marie Burns, M.Sc., Pawel Durek, Ph.D., et al. Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus, New England Journal of Medicine (2020). DOI:10.1056/NEJMoa2023325.